Professor Thomas R Barnes

Publications


Journals

  • Barnes TR; Drake MJ; Paton C. (Jan 2012). Nocturnal enuresis with antipsychotic medication. Br J Psychiatry. 200:7-9. DOI.
  • Harrison PJ; Baldwin DS; Barnes TRE; Burns T; Ebmeier KP; Ferrier IN; Nutt DJ. (Oct 2011). No psychiatry without psychopharmacology. BRIT J PSYCHIAT. 199:263-265. DOI.
  • Huddy VC; Hodgson TL; Ron MA; Barnes TRE; Joyce EM. (Sep 2011). Abnormal negative feedback processing in first episode schizophrenia: evidence from an oculomotor rule switching task. PSYCHOL MED. 41:1805-1814. DOI.
  • Barnes TR; Paton C. (Aug 2011). Improving prescribing practice in psychiatry: the experience of the Prescribing Observatory for Mental Health (POMH-UK). Int Rev Psychiatry. 23:328-335. DOI.
  • Leeson VC; Sharma P; Harrison M; Ron MA; Barnes TR; Joyce EM. (Jul 2011). IQ trajectory, cognitive reserve, and clinical outcome following a first episode of psychosis: a 3-year longitudinal study. Schizophr Bull. 37:768-777. DOI.
  • Paton C; Flynn A; Shingleton-Smith A; McIntyre S; Bhaumik S; Rasmussen J; Hardy S; Barnes T. (Jul 2011). Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. J INTELL DISABIL RES. 55:665-674. DOI.
  • Crawford MJ; Kakad S; Rendel C; Mansour NA; Crugel M; Liu KW; Paton C; Barnes TR. (Nov 2011). Medication prescribed to people with personality disorder: the influence of patient factors and treatment setting. Acta Psychiatr Scand. 124:396-402. DOI.
  • Barnes TRE; Paton C. (10 Jun 2011). UNCERTAINTIES PAGE Do antidepressants improve negative symptoms in schizophrenia?. BRIT MED J. 342. DOI.
  • Barnes TR; Paton C. (May 2011). Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs. 25:383-399. DOI.
  • Barnes MR; Huxley-Jones J; Maycox PR; Lennon M; Thornber A; Kelly F; Bates S; Taylor A; et alReid J; Jones N; Schroeder J; Scorer CA; Davies C; Hagan JJ; Kew JN; Angelinetta C; Akbar T; Hirsch S; Mortimer AM; Barnes TR; de Belleroche J. (Aug 2011). Transcription and pathway analysis of the superior temporal cortex and anterior prefrontal cortex in schizophrenia. J Neurosci Res. 89:1218-1227. DOI.
  • Barnes TR; Schizophrenia Consensus Group of British Association for Psychopharmacology. (May 2011). Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 25:567-620. DOI.
  • Barnes TR; Paton C. (2011). Do antidepressants improve negative symptoms in schizophrenia?. BMJ. 342:d3371.
  • Collins N; Barnes TRE; Shingleton-Smith A; Gerrett D; Paton C. (12 Oct 2010). Standards of lithium monitoring in mental health trusts in the UK. BMC PSYCHIATRY. 10. DOI.
  • Crawford MJ; Killaspy H; Kalaitzaki E; Barrett B; Byford S; Patterson S; Soteriou T; O'Neill FA; et alClayton K; Maratos A; Barnes TR; Osborn D; Johnson T; King M; Tyrer P; Waller D. (2010). The MATISSE study: a randomised trial of group art therapy for people with schizophrenia. BMC Psychiatry. 10:65. DOI.
  • Pope A; Adams C; Paton C; Weaver T; Barnes TR. (Jul 2010). Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. Br J Psychiatry. 197:67-72. DOI.
  • Kane JM; Barnes TRE; Correll CU; Sachs G; Buckley P; Eudicone J; McQuade R; Tran QV; et alPikalov A; Assuncao-Talbott S. (Jul 2010). Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J PSYCHOPHARMACOL. 24:1019-1029. DOI.
  • Paton C; Barnes TR; Shingleton-Smith A; McAllister-Williams RH; Kirkbride J; Jones PB; McIntyre S; POMH-UK project team. (Dec 2010). Lithium in bipolar and other affective disorders: prescribing practice in the UK. J Psychopharmacol. 24:1739-1746. DOI.
  • Gutiérrez-Galve L; Wheeler-Kingshott CA; Altmann DR; Price G; Chu EM; Leeson VC; Lobo A; Barker GJ; et alBarnes TR; Joyce EM; Ron MA. (1 Jul 2010). Changes in the frontotemporal cortex and cognitive correlates in first-episode psychosis. Biol Psychiatry. 68:51-60. DOI.
  • Price G; Cercignani M; Chu EM; Barnes TRE; Barker GJ; Joyce EM; Ron MA. (1 Jan 2010). Brain pathology in first-episode psychosis: Magnetization transfer imaging provides additional information to MRI measurements of volume loss. NEUROIMAGE. 49:185-192. DOI.
  • Dimic S; Wildgrube C; McCabe R; Hassan I; Barnes TRE; Priebe S. (2010). Non-Verbal Behaviour of Patients with Schizophrenia in Medical Consultations - A Comparison with Depressed Patients and Association with Symptom Levels. PSYCHOPATHOLOGY. 43:216-222. DOI.
  • Maycox PR; Kelly F; Taylor A; Bates S; Reid J; Logendra R; Barnes MR; Larminie C; et alJones N; Lennon M; Davies C; Hagan JJ; Scorer CA; Angelinetta C; Akbar MT; Hirsch S; Mortimer AM; Barnes TR; de Belleroche J. (Dec 2009). Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. Mol Psychiatry. 14:1083-1094. DOI.
  • Barnes TRE; Shingleton-Smith A; Paton C. (Nov 2009). Antipsychotic long-acting injections: prescribing practice in the UK. BRIT J PSYCHIAT. 195:S37-S42. DOI.
  • Leeson VC; Robbins TW; Franklin C; Harrison M; Harrison I; Ron MA; Barnes TR; Joyce EM. (Nov 2009). Dissociation of long-term verbal memory and fronto-executive impairment in first-episode psychosis. Psychol Med. 39:1799-1808. DOI.
  • Leeson VC; Robbins TW; Matheson E; Hutton SB; Ron MA; Barnes TR; Joyce EM. (15 Sep 2009). Discrimination learning, reversal, and set-shifting in first-episode schizophrenia: stability over six years and specific associations with medication type and disorganization syndrome. Biol Psychiatry. 66:586-593. DOI.
  • Huddy VC; Aron AR; Harrison M; Barnes TR; Robbins TW; Joyce EM. (Jun 2009). Impaired conscious and preserved unconscious inhibitory processing in recent onset schizophrenia. Psychol Med. 39:907-916. DOI.
  • James L; Paton C; Lelliott P; Barnes TRE; Taylor D. (Apr 2009). Mood stabilizers and teratogenicity - prescribing practice and awareness amongst practising psychiatrists. J MENT HEALTH. 18:137-143. DOI.
  • Roiser JP; Stephan KE; den Ouden HEM; Barnes TRE; Friston KJ; Joyce EM. (Feb 2009). Do patients with schizophrenia exhibit aberrant salience?. PSYCHOL MED. 39:199-209. DOI.
  • Leeson VC; Barnes TR; Hutton SB; Ron MA; Joyce EM. (Jan 2009). IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr Res. 107:55-60. DOI.
  • Zammit S; Moore THM; Lingford-Hughes A; Barnes TRE; Jones PB; Burke M; Lewis G. (Nov 2008). Effects of cannabis use on outcomes of psychotic disorders: systematic review. BRIT J PSYCHIAT. 193:357-363. DOI.
  • Barnes TR; Leeson VC; Mutsatsa SH; Watt HC; Hutton SB; Joyce EM. (Sep 2008). Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry. 193:203-209. DOI.
  • Leeson VC; Barnes TR; Harrison M; Matheson E; Harrison I; Mutsatsa SH; Ron MA; Joyce EM. (Mar 2010). The relationship between IQ, memory, executive function, and processing speed in recent-onset psychosis: 1-year stability and clinical outcome. Schizophr Bull. 36:400-409. DOI Open Access copy.
  • Davies LM; Barnes TRE; Jones PB; Lewis S; Gaughran F; Hayhurst K; Markwick A; Lloyd H; et alCUTLASS Team. (Jul 2008). A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine. VALUE HEALTH. 11:549-562. DOI.
  • Barnes TR; Paton C; Hancock E; Cavanagh MR; Taylor D; Lelliott P; UK Prescribing Observatory for Mental Health. (Jul 2008). Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme. Acta Psychiatr Scand. 118:26-33. DOI.
  • Paton C; Barnes TR; Cavanagh MR; Taylor D; Lelliott P; POMH-UK project team. (Jun 2008). High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry. 192:435-439. DOI.
  • Ohlsen RI; Williamson R; Yusufi B; Mullan J; Irving D; Mukherjee S; Page E; Aitchison KJ; et alBarnes TRE. (May 2008). Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale measured in patients treated with clozapine. J PSYCHOPHARMACOL. 22:323-329. DOI.
  • Price G; Cercignani M; Parker GJM; Altmann DR; Barnes TRE; Barker GJ; Joyce EM; Ron MA. (1 Feb 2008). White matter tracts in first-episode psychosis: A DTI tractography study of the uncinate fasciculus. NEUROIMAGE. 39:949-955. DOI.
  • Turkington D; Sensky T; Scott J; Barnes TRE; Nur U; Siddle R; Hammond K; Samarasekara N; et alKingdon D. (Jan 2008). A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: A five-year follow-up. SCHIZOPHR RES. 98:1-7. DOI.
  • Harrison I; Joyce EM; Mutsatsa SH; Hutton SB; Huddy V; Kapasi M; Barnes TR. (Jan 2008). Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol Med. 38:79-88. DOI.
  • Price G; Cercignani M; Parker GJM; Altmann DR; Barnes TRE; Barker GJ; Joyce EM; Ron MA. (Dec 2007). Abnormal brain connectivity in first-episode psychosis: A diffusion MRI tractography study of the corpus callosum (vol 35, pg 458, 2007). NEUROIMAGE. 38:766-766. DOI.
  • Barnes TR; Paton C; Cavanagh MR; Hancock E; Taylor DM; UK Prescribing Observatory for Mental Health. (Nov 2007). A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophr Bull. 33:1397-1403. DOI.
  • James L; Barnes TR; Lelliott P; Taylor D; Paton C. (Nov 2007). Informing patients of the teratogenic potential of mood stabilizing drugs: a case note review of the practice of psychiatrists. J Psychopharmacol. 21:815-819. DOI.
  • Huddy VC; Hodgson TL; Kapasi M; Mutsatsa SH; Harrison I; Barnes TR; Joyce EM. (Aug 2007). Gaze strategies during planning in first-episode psychosis. J Abnorm Psychol. 116:589-598. DOI.
  • Moore TH; Zammit S; Lingford-Hughes A; Barnes TR; Jones PB; Burke M; Lewis G. (28 Jul 2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 370:319-328. DOI.
  • Davies LM; Lewis S; Jones PB; Barnes TR; Gaughran F; Hayhurst K; Markwick A; Lloyd H; et alCUtLASS team. (Jul 2007). Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry. 191:14-22. DOI.
  • Yusufi B; Mukherjee S; Flanagan R; Paton C; Dunn G; Page E; Barnes TR. (Jul 2007). Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. Int Clin Psychopharmacol. 22:238-243. DOI.
  • Price G; Cercignani M; Parker GJM; Altmann DR; Barnes TRE; Barker GJ; Joyce EM; Ron MA. (1 Apr 2007). Abnormal brain connectivity in first-episode psychosis: A diffusion MRI tractography study of the corpus callosum. NEUROIMAGE. 35:458-466. DOI.
  • Price G; Cercignani M; Parker GJ; Altmann DR; Barnes TR; Barker GJ; Joyce EM; Ron MA. (1 Apr 2007). Abnormal brain connectivity in first-episode psychosis: a diffusion MRI tractography study of the corpus callosum. Neuroimage. 35:458-466. DOI.
  • Paton C; Whittington C; Barnes TR. (Apr 2007). Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol. 27:198-204. DOI.
  • Samarasekera N; Kingdon D; Siddle R; O'Carroll M; Scott JL; Sensky T; Barnes TRE; Turkington D. (Mar 2007). Befriending patients with medication-resistant schizophrenia: Can psychotic symptoms predict treatment response?. PSYCHOL PSYCHOTHER-T. 80:97-106. DOI.
  • Samarasekera N; Kingdon D; Siddle R; O'Carroll M; Scott JL; Sensky T; Barnes TR; Turkington D. (Mar 2007). Befriending patients with medication-resistant schizophrenia: can psychotic symptoms predict treatment response?. Psychol Psychother. 80:97-106. DOI.
  • Steeruwits A; Barnes TRE; Fehler J; Ohlsen R; Curtis VA. (Mar 2007). Pharmacological management of acute mania - does current prescribing practice reflect treatment guidelines?. J PSYCHOPHARMACOL. 21:206-209. DOI.
  • Price G; Cercignani M; Bagary MS; Barnes TRE; Barker GJ; Joyce EM; Ron MA. (Oct 2006). A volumetric MRI and magnetization transfer imaging follow-up study of patients with first-episode schizophrenia. SCHIZOPHR RES. 87:100-108. DOI.
  • Lewis SW; Barnes TR; Davies L; Murray RM; Dunn G; Hayhurst KP; Markwick A; Lloyd H; et alJones PB. (Oct 2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 32:715-723. DOI.
  • Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; et alLewis SW. (Oct 2006). Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 63:1079-1087. DOI.
  • Mutsatsa SH; Joyce EM; Hutton SB; Barnes TR. (Sep 2006). Relationship between insight, cognitive function, social function and symptomatology in schizophrenia: the West London first episode study. Eur Arch Psychiatry Clin Neurosci. 256:356-363. DOI.
  • Streeruwitz A; Barnes TR; Fehler J; Ohlsen RI; Curtis V. (4 Aug 2006). Pharmacological management of acute mania - does current prescribing practice reflect treatment guidelines?. J Psychopharmacol. Publisher weblink DOI.
  • Barnes TRE; Davison S; Ferrier IN; Howard R; Kerwin R; King DJ; Lelliott P; Lewis S; et alMackay AVP; McCartney W; Paton C; Pereira S; Procter A; Pruce D; Wellman N. (May 2006). Consensus statement on high-dose antipsychotic medication. CR138, Royal College of Psychiatrists.
  • Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; et alMarkwick A; Lloyd H; Dunn G. (May 2006). Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess. 10:iii-165.
  • Barnes TR; Mutsatsa SH; Hutton SB; Watt HC; Joyce EM. (Mar 2006). Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry. 188:237-242. DOI.
  • Price G; Cercignani M; Bagary MS; Barnes TRE; Joyce EM. (2006). Structural brain changes in schizophrenia; a volumetric MRI and magnetisation transfer imaging follow-up study of first episode patients. Schizophrenia Research. 87:100-108.
  • Joyce EM; Hutton SB; Mutsatsa SH; Barnes TRE. (Dec 2005). Cognitive heterogeneity in first-episode schizophrenia. BRIT J PSYCHIAT. 187:516-522.
  • Joyce EM; Hutton SB; Mutsatsa SH; Barnes TR. (Dec 2005). Cognitive heterogeneity in first-episode schizophrenia. Br J Psychiatry. 187:516-522. DOI.
  • Green MF; Barnes TR; Danion JM; Gallhofer B; Meltzer HY; Pantelis C. (1 May 2005). The FOCIS international survey on psychiatrists' opinions on cognition in schizophrenia. Schizophr Res. 74:253-261. DOI.
  • Lloyd HM; Markwick AJ; Page ER; Lewis S; Barnes TRE. (2005). Attitudes to atypical and conventional antipsychotic drug treatment in clinicians participating in the CUtLASS study. International Journal of Psychiatry in Clinical Practice. 9:35-40.
  • Flanagan RJ; Spencer EP; Morgan PE; Barnes TRE; Dunk L. (2005). Suspected clozapine poisoning in the UK/Eire. Forensic Science International. 155:91-99.
  • Barnes TRE; DursunS. (2005). Treatment resistance in schizophrenia. Psychiatry. 11, 4:68-70.
  • Bagary MS; Hutton SB; Symms MR; Barker GJ; Mutsatsa SH; Barnes TRE; Joyce EM; Ron MA. (1 Nov 2004). Structural neural networks subserving oculomotor function in first-episode schizophrenia. BIOL PSYCHIAT. 56:620-627. DOI.
  • Bagary MS; Hutton SB; Symms MR; Barker GJ; Mutsatsa SH; Barnes TR; Joyce EM; Ron MA. (1 Nov 2004). Structural neural networks subserving oculomotor function in first-episode schizophrenia. Biol Psychiatry. 56:620-627. DOI.
  • Hutton SB; Huddy V; Barnes TR; Robbins TW; Crawford TJ; Kennard C; Joyce EM. (15 Oct 2004). The relationship between antisaccades, smooth pursuit, and executive dysfunction in first-episode schizophrenia. Biol Psychiatry. 56:553-559. DOI.
  • Weaver T; Stimson G; Tyrer P; Barnes T; Renton A; COSMIC Study Team. (Aug 2004). What are the implications for clinical management and service development of prevalent comorbidity in UK mental health and substance misuse treatment populations?. DRUG-EDUC PREV POLIC. 11:329-348. DOI.
  • Pantelis C; Harvey CA; Plant G; Fossey E; Maruff P; Stuart GW; Brewer WJ; Nelson HE; et alRobbins TW; Barnes TR. (May 2004). Relationship of behavioural and symptomatic syndromes in schizophrenia to spatial working memory and attentional set-shifting ability. Psychol Med. 34:693-703. DOI.
  • Fitzpatrick NK; Shah S; Walker N; Nourmand S; Tyrer PJ; Barnes TR; Higgitt A; Hemingway H. (Feb 2004). The determinants and effect of shared care on patient outcomes and psychiatric admissions - an inner city primary care cohort study. Soc Psychiatry Psychiatr Epidemiol. 39:154-163. DOI.
  • Lima AR; Bacalcthuk J; Barnes TR; Soares-Weiser K. (2004). Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. CD001946. DOI.
  • Barnes TRE. (2004). Pharmacological strategies for relapse prevention in schizophrenia. Psychiatry. 10, 3:37-40.
  • Weaver T; Stimson G; Tyrer P; Barnes TRE; Renton A. (2004). What are the implications for clinical management and service development of prevalent co-morbidity in UK mental health and substance misuse treatment populations?. Drugs: Education, Policy & Prevention. 4, 11:329-348.
  • Mutsatsa SH; Joyce EM; Hutton SB; Webb E; Gibbins H; Paul S; Barnes TR. (Dec 2003). Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand. 108:439-446.
  • Barnes TR. (Dec 2003). The Barnes Akathisia Rating Scale--revisited. J Psychopharmacol. 17:365-370.
  • Weaver T; Madden P; Charles V; Stimson G; Renton A; Tyrer P; Barnes T; Bench C; et alMiddleton H; Wright N; Paterson S; Shanahan W; Seivewright N; Ford C; Comorbidity of Substance Misuse and Mental Illness Collaborative study team. (Oct 2003). Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. Br J Psychiatry. 183:304-313.
  • Flanagan RJ; Yusufi B; Barnes TR. (Jul 2003). Comparability of whole-blood and plasma clozapine and norclozapine concentrations. Br J Clin Pharmacol. 56:135-138.
  • Leucht S; Barnes TR; Kissling W; Engel RR; Correll C; Kane JM. (Jul 2003). Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 160:1209-1222.
  • Fitzpatrick NK; Thompson CJ; Hemingway H; Barnes TRE; Higgitt A; Molloy C; Hargreaves S. (2003). Acute mental health admissions in inner London: changes in patient characteristics and clinical admission thresholds between 1988 and 1998. Psychiatric Bulletin. 27:7-11.
  • Singh S; Wright C; Joyce E; Barnes TRE; Burns T.. (2003). Developing early intervention services in the NHS: a survey to guide workforce and training needs. Psychiatric Bulletin. 27:254-258.
  • Joyce E; Hutton S; Mutsatsa S; Gibbins H; Webb E; Paul S; Robbins T; Barnes T. (Sep 2002). Executive dysfunction in first-episode schizophrenia and relationship to duration of untreated psychosis: the West London Study. Br J Psychiatry Suppl. 43:s38-s44.
  • Hutton SB; Murphy FC; Joyce EM; Rogers RD; Cuthbert I; Barnes TR; McKenna PJ; Sahakian BJ; et alRobbins TW. (1 Jun 2002). Decision making deficits in patients with first-episode and chronic schizophrenia. Schizophr Res. 55:249-257.
  • Mutsatsa SH; Joyce EM; Hutton SB; Webb; Paul S; Barnes TRE. (15 Jan 2002). Attitudes towards medication in schizophrenia: The West London first-episode study. SCHIZOPHR RES. 53:205-205.
  • Joyce EM; Hutton SB; Mutsatsa SH; Webb E; Paul S; Barnes TRE. (15 Jan 2002). Contribution of IQ to risk of schizophrenia and cognitive profile at first episode: The West London study. SCHIZOPHR RES. 53:140-140.
  • Lima AR; Weiser KV; Bacaltchuk J; Barnes TR. (2002). Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. CD003727. DOI.
  • Lima AR; Soares-Weiser K; Bacaltchuk J; Barnes TR. (2002). Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. CD001950. DOI.
  • Barnes TRE; Pant A. (2002). Long-term course and outcome in schizophrenia. Psychiatry. 1:34-36.
  • Hutton SB; Joyce EM; Barnes TR; Kennard C. (2002). Saccadic distractibility in first-episode schizophrenia. Neuropsychologia. 40:1729-1736.
  • Duke PJ; Pantelis C; McPhillips MA; Barnes TR. (Dec 2001). Comorbid non-alcohol substance misuse among people with schizophrenia: epidemiological study in central London. Br J Psychiatry. 179:509-513.
  • Hutton SB; Crawford TJ; Gibbins H; Cuthbert I; Barnes TR; Kennard C; Joyce EM. (Sep 2001). Short and long term effects of antipsychotic medication on smooth pursuit eye tracking in schizophrenia. Psychopharmacology (Berl). 157:284-291. DOI.
  • Pantelis C; Stuart GW; Nelson HE; Robbins TW; Barnes TR. (Aug 2001). Spatial working memory deficits in schizophrenia: relationship with tardive dyskinesia and negative symptoms. Am J Psychiatry. 158:1276-1285.
  • Puri BK; Hutton SB; Saeed N; Oatridge A; Hajnal JV; Duncan L; Chapman MJ; Barnes TR; et alBydder GM; Joyce EM. (10 Apr 2001). A serial longitudinal quantitative MRI study of cerebral changes in first-episode schizophrenia using image segmentation and subvoxel registration. Psychiatry Res. 106:141-150.
  • Barnes TRE; Joyce EM. (2001). Antipsychotic drug treatment: recent advances. Curr Opin Psychiatry. 1, 14:25-37.
  • Barnes TRE; Joyce EM. (2001). Antipsychotic drug treatment: recent advances. Curr Opin Psychiatry. 1, 14:25-37.
  • Hutton SB; Cuthbert I; Crawford TJ; Kennard C; Barnes TR; Joyce EM. (Jan 2001). Saccadic hypometria in drug-naive and drug-treated schizophrenic patients: a working memory deficit?. Psychophysiology. 38:125-132.
  • Barnes T. (Nov 2000). Movement disorders in neurology and neuropsychiatry (2nd edition). BRIT J PSYCHIAT. 177:472-473.
  • Hutton SB; Crawford TJ; Kennard C; Barnes TR; Joyce EM. (2000). Smooth pursuit eye tracking over a structured background in first-episode schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 250:221-225.
  • Barnes TR; Hutton SB; Chapman MJ; Mutsatsa S; Puri BK; Joyce EM. (Sep 2000). West London first-episode study of schizophrenia. Clinical correlates of duration of untreated psychosis. Br J Psychiatry. 177:207-211.
  • Berardi D; Giannelli A; Barnes TRE. (Jul 2000). Clinical correlates of akathisia in acute psychiatric inpatients. INT CLIN PSYCHOPHARM. 15:215-219.
  • Barnes T. (May 2000). A guide to the extrapyramidal side-effects of antipsychotic drugs. BRIT J PSYCHIAT. 176:502-502.
  • Poyurovsky M; Nave R; Epstein R; Tzischinsky O; Schneidman M; Barnes TRE; Weizman A; Lavie P. (May 2000). Actigraphic monitoring (actigraphy) of circadian locomotor activity in schizophrenic patients with acute neuroleptic-induced akathisia. EUR NEUROPSYCHOPHARM. 10:171-176.
  • Mutsatsa SH; Barnes TRE; Hutton SB; Cuthbert I; Joyce EM. (3 Jan 2000). A cross-sectional study of medication compliance: The west London first-episode schizophrenia study. SCHIZOPHR RES. 41:223-223.
  • Hutton SB; Cuthbert I; Mutsatsa S; Kennard C; Barnes TRE; Joyce EM. (3 Jan 2000). Antisaccade and smooth pursuit performance in patients with schizophrenia and obsessive compulsive disorder. SCHIZOPHR RES. 41:154-154.
  • McLeod HJ; Barnes TRE; Burgess A. (3 Jan 2000). Autobiographical memory specificity and response initiation and suppression deficits in schizophrenia. SCHIZOPHR RES. 41:279-280.
  • Joyce EM; Hutton SB; Barber FZ; Cuthbert I; Mutsatsa S; Gibbins H; Barnes TRE. (3 Jan 2000). Relationship between IQ and memory and executive function in first episode schizophrenia. SCHIZOPHR RES. 41:276-276.
  • Hutton SB; Cuthbert I; Mutsata S; Kennard C; Barnes TRE; Joyce EM. (3 Jan 2000). Saccadic distractibility in first-episode schizophrenia. SCHIZOPHR RES. 41:155-155.
  • Hutton SB; Crawford T; Gibbins H; Cuthbert I; Kennard C; Barnes TRE; Joyce EM. (3 Jan 2000). Smooth pursuit dysfunction in schizophrenia: A comprehensive analysis in first-episode and chronic patients. SCHIZOPHR RES. 41:155-155.
  • Hutton SB; Cuthbert I; Mutsatsa S; Kennard C; Barnes TRE; Joyce EM. (3 Jan 2000). The effects of typical and atypical neuroleptics on neuropsychological and oculomotor function in first-episode schizophrenia. SCHIZOPHR RES. 41:40-40.
  • Pantelis C; Barber FZ; Barnes TRE; Nelson HE; Owen AM; Robbins TW. (22 Jun 1999). Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. SCHIZOPHR RES. 37:251-270.
  • Curson DA; Duke PJ; Harvey CA; Pantelis C; Barnes TRE. (25 May 1999). Four behavioural syndromes of schizophrenia: a replication in a second inner-London epidemiological sample. SCHIZOPHR RES. 37:165-176.
  • Joyce EM; Hutton SB; Ambery FZ; Robbins TW; Barnes TRE. (Apr 1999). Improvement of deterioration in different executive cognitive processes early in the course of schizophrenia. SCHIZOPHR RES. 36:138-138.
  • Hutton SB; Cuthbert I; Crawford TJ; Kennard C; Barnes TRE; Joyce EM. (Apr 1999). Saccadic hypometria in drug-naive and drug-treated schizophrenic patients: A working memory deficit?. SCHIZOPHR RES. 36:264-264.
  • Barnes TRE; Hutton SB; Chapman MJ; Mutsatsa S; Puri BK; Joyce EM. (Apr 1999). West London first-episode study of schizophrenia: Clinical correlates of duration of untreated psychosis at first presentation to psychiatric services. SCHIZOPHR RES. 36:12-13.
  • McPhillips MA; Strang J; Barnes TRE. (Oct 1998). Hair analysis - New laboratory ability to test for substance use. BRIT J PSYCHIAT. 173:287-290.
  • Puri BK; Saeed N; Oatridge A; Hajnal JV; Hutton SB; Duncan LJ; Chapman MJ; Barnes TRE; et alBydder GM; Joyce EM. (Jan 1998). A longitudinal MRI study of first-episode schizophrenia: Assessment of cerebral changes and quantitation of ventricular changes. SCHIZOPHR RES. 29:76-76.
  • Sensky T; Siddle R; O'Carroll M; Scott J; Turkington D; Kingdon D; Dudley R; McPhillips M; et alJohns C; Scott JL; Barnes TRE. (Jan 1998). A randomized controlled trial of cognitive behaviour therapy in the management of treatment-resistant schizophrenia. SCHIZOPHR RES. 29:164-164.
  • Chapman M; Hutton S; Duncan LJ; Puri BK; Joyce EM; Barnes TRE. (Jan 1998). Core negative symptoms and social functioning: West London first-episode schizophrenia study. SCHIZOPHR RES. 29:193-194.
  • Joyce EM; Hutton SB; Duncan LJ; Chapman MJ; Puri BK; Robbins TW; Barnes TRE. (Jan 1998). Executive function in first episode schizophrenia: Improvement at one year. SCHIZOPHR RES. 29:53-53.
  • McPhillips MA; Hillier R; Hutton S; Duncan LJ; Puri BK; Joyce EM; Barnes TRE. (Jan 1998). Neurobiological variables at presentation and compliance with antipsychotic medication at six months: West London first-episode schizophrenia study. SCHIZOPHR RES. 29:195-196.
  • Hutton SB; Crawford TJ; Duncan LJ; Chapman M; Puri BK; Kennard C; Barnes TRE; Joyce EM. (Jan 1998). Oculomotor abnormalities in first episode schizophrenic patients: A follow-up study. SCHIZOPHR RES. 29:115-116.
  • Halstead SM; Barnes TRE; Hennessy RE; Goswami U. (Jan 1998). Six year follow-up study of chronic akathisia in a schizophrenic inpatient population. SCHIZOPHR RES. 29:177-177.
  • Hutton SB; Crawford TJ; Duncan LJ; Chapman M; Puri BK; Kennard C; Barnes TRE; Joyce EM. (Jan 1998). Smooth pursuit performance over a structured background in first episode schizophrenic patients and controls. SCHIZOPHR RES. 29:116-116.
  • Hutton SB; Crawford TJ; Duncan LJ; Chapman M; Puri BK; Kennard C; Robbins TW; Barnes TRE; et alJoyce EM. (Jan 1998). The relationship between neuropsychological and oculomotor deficits in first episode schizophrenia. SCHIZOPHR RES. 29:52-52.
  • Speller JC; Barnes TRE; Curson DA; Pantelis C; Alberts JL. (Dec 1997). One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms - Amisulpride v. haloperidol. BRIT J PSYCHIAT. 171:564-568.
  • Pantelis C; Barnes TRE; Nelson HE; Tanner S; Weatherley L; Owen AM; Robbins TW. (Oct 1997). Frontal-striatal cognitive deficits in patients with chronic schizophrenia. BRAIN. 120:1823-1843.
  • Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CGG; Murphy AL; Bowden CL; OBrien CP; et alSteinbook RM; Wagner RL; Pitts WM; Crabtree B; Corrigan MHN; Lohr JB; Miller AL; Ereshefsky L; Anderson CB; Knesevich MA; Rotrosen J; Owen RR; Karson CN; Lindenmayer JP; Pfefferbaum A; Faustman WO; Keck PE; Patterson WM; Riesenberg RA; Gladson MB; Kolin IS; Barnes TRE; Sensky T; Riccio M; Franks S; Jolley A; Hallstrom C; Bennie E; Darcourt G; Patris M; DeSilva M; Patel AG; Fleischhacker WW; Dietzel M; Seifertova D; Vinar O; Faltus F; Bitter I; Ozsvath K; Shaw SH; Mahapatra SN; Szulecka TK; Sundararajan K; Creaven F; Lynch J; Klieser E; Cooper SJ; Aschauer H. (Jun 1997). Quetiapine in patients with schizophrenia - A high- and low-dose double-blind comparison with placebo. ARCH GEN PSYCHIAT. 54:549-557.
  • McPhillips MA; Duke P; Pantelis C; Barnes TRE. (Mar 1997). Comorbid substance misuse among people with schizophrenia in the community: An epidemiological study in central London. SCHIZOPHR RES. 24:256-256.
  • Barnes TRE; McPhillips MA; Hillier R; Puri BK; Joyce E. (Mar 1997). Compliance with maintenance medication in first-episode schizophrenia. SCHIZOPHR RES. 24:205-205.
  • Hutton SB; Puri BK; Duncan LJ; Robbins TW; Barnes TRE; Joyce EM. (Mar 1997). Memory and executive function in first episode schizophrenia. SCHIZOPHR RES. 24:109-109.
  • Hutton SB; Crawford TJ; Puri BK; Duncan LJ; Kennard C; Barnes TRE; Joyce EM. (Mar 1997). Smooth pursuit abnormalities in first episode schizophrenic patients. SCHIZOPHR RES. 24:243-243.
  • Barnes TRE; Puri BK; Chapman MJ; Hutton SB; Joyce E. (Mar 1997). Spontaneous dyskinesia in first-episode schizophrenia. SCHIZOPHR RES. 24:269-269.
  • McPhillips MA; Barnes TRE. (Jan 1997). Negative symptoms. CURR OPIN PSYCHIATR. 10:30-35.
  • Barnes TRE; McPhillips MA. (Oct 1996). Antipsychotic-induced extrapyramidal symptoms - Role of anticholinergic drugs in treatment. CNS DRUGS. 6:315-330.
  • Haw CM; Barnes TRE; Clark K; Crichton P; Kohen D. (Jul 1996). Movement disorder in Down's syndrome: A possible marker of the severity of mental handicap. MOVEMENT DISORD. 11:395-403.
  • Warner JP; Barnes TRE; Henry JA. (Apr 1996). Electrocardiographic changes in patients receiving neuroleptic medication. ACTA PSYCHIAT SCAND. 93:311-313.
  • Harvey CA; Curson DA; Pantelis C; Taylor J; Barnes TRE. (Feb 1996). Four behavioural syndromes of schizophrenia. SCHIZOPHR RES. 18:IVA3-IVA3.
  • Khan NS; Das I; Puri BK; deBelleroche J; Joyce EM; Barnes TRE; Hirsch SR. (Feb 1996). Increased platelet calcium mobilization and nitric oxide synthase activity - Implications in schizophrenia. SCHIZOPHR RES. 18:VIII4-VIII4.
  • Durnin AT; Mortimer A; Barnes TRE; Hirsch SR; deBelleroche J. (Feb 1996). Is the expression of cholecystokinin mRNA in schizophrenia region specific?. SCHIZOPHR RES. 18:XC3-XC3.
  • Hutton SB; Crawford TJ; Puri BK; Kennard C; Joyce EM; Barnes TRE. (Feb 1996). Saccadic and smooth pursuit eye movement abnormalities in first episode schizophrenia. SCHIZOPHR RES. 18:XIII4-XIII4.
  • McPhillips MA; Kelly F; Barnes TRE; GeneCos N; Duke P; Clarke K. (Feb 1996). Substance misuse among schizophrenics in the community: A follow-up study using hair analysis. SCHIZOPHR RES. 18:IIIC5-IIIC5.
  • Humphries CR; Mortimer A; Barnes T; Hirsch S; deBelleroche J. (Feb 1996). The expression of the N-methyl-D-aspartate receptor subunit NR-1 messenger RNA in schizophrenia. SCHIZOPHR RES. 18:XB3-XB3.
  • Hutton SB; Puri BK; Barnes TRE; Robbins TW; Joyce EM. (Feb 1996). Visuospatial memory in first episode schizophrenia. SCHIZOPHR RES. 18:XIII6-XIII6.
  • Barnes TRE; Kane JM. (Jan 1996). Choosing between old and new antipsychotics. CURR OPIN PSYCHIATR. 9:41-44.
  • Virgo L; Humphries C; Mortimer A; Barnes T; Hirsch S; de Belleroche J. (15 May 1995). Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia. Biol Psychiatry. 37:694-701. DOI.
  • DEBELLEROCHE J; HUMPHRIES C; VIRGO L; MORTIMER A; BARNES TRE; HIRSCH SR. (Apr 1995). ANALYSIS OF SPECIFIC NEURONAL POPULATIONS IN SCHIZOPHRENIA BY IN-SITU HYBRIDIZATION - FUNCTIONAL AND REGIONAL CORRELATIONS. SCHIZOPHR RES. 15:56-57.
  • BARNES TRE; WARNER J; HENRY JA. (Apr 1995). SIDE-EFFECTS AND TARDIVE-DYSKINESIA. SCHIZOPHR RES. 15:205-205.
  • HUMPHRIES CR; VIRGO L; MORTIMER A; BARNES T; HIRSCH S; DEBELLEROCHE J. (Apr 1995). THE EXPRESSION OF THE N-METHYL-D-ASPARTATE RECEPTOR SUBUNIT NR-1 IS DECREASED IN SCHIZOPHRENIA. SCHIZOPHR RES. 15:60-61.
  • KANE JM; BARNES TRE. (Jan 1995). SCHIZOPHRENIA RESEARCH - CHALLENGES AND OPPORTUNITIES. CURR OPIN PSYCHIATR. 8:19-20.
  • BOWEN JT; BARNES TRE. (Nov 1994). THE CLINICAL CHARACTERISTICS OF SCHIZOPHRENIC-PATIENTS CONSENTING OR NOT CONSENTING TO A PLACEBO-CONTROLLED TRIAL OF ANTIPSYCHOTIC MEDICATION. HUM PSYCHOPHARM CLIN. 9:423-433.
  • MOLLER HJ; VANPRAAG HM; AUFDEMBRINKE B; BAILEY P; BARNES TRE; BECK J; BENTSEN H; EICH FX; et alFARROW L; FLEISCHHACKER WW; GERLACH J; GRAFFORD K; HENTSCHEL B; HERTKORN A; HEYLEN S; LECRUBIER Y; LEONARD JP; MCKENNA P; MAIER W; PEDERSEN V; RAPPARD A; REIN W; RYAN J; NIELSEN MS; STIEGLITZ RD; WEGENER G; WILSON J. (Jun 1994). NEGATIVE SYMPTOMS IN SCHIZOPHRENIA - CONSIDERATIONS FOR CLINICAL-TRIALS. PSYCHOPHARMACOLOGY. 115:221-228.
  • LIDDLE PF; BARNES TRE. (May 1994). UNTITLED - REPLY. BRIT J PSYCHIAT. 164:702-702.
  • HALSTEAD SM; BARNES TRE; SPELLER JC. (Feb 1994). AKATHISIA - PREVALENCE AND ASSOCIATED DYSPHORIA IN AN INPATIENT POPULATION WITH CHRONIC-SCHIZOPHRENIA. BRIT J PSYCHIAT. 164:177-183.
  • VIRGO L; DEBELLEROCHE J; BARNES T; MORTIMER A; HIRSCH S. (Jan 1994). ALTERATIONS IN THE EXPRESSION OF NITRIC-OXIDE SYNTHASE IN SCHIZOPHRENIA. SCHIZOPHR RES. 11:122-122.
  • PANTELIS C; BARNES TRE; NELSON HE; SAHAKIAN B; ROBBINS TW. (Jan 1994). COGNITIVE DEFICITS IN SCHIZOPHRENIA COMPARED WITH FRONTAL-LOBE, TEMPORAL-LOBE AND BASAL GANGLIA DISORDERS. SCHIZOPHR RES. 11:152-152.
  • VIRGO L; DEBELLEROCHE J; BARNES T; MORTIMER A; HIRSCH S. (Jan 1994). DIFFERENTIAL CHANGES IN GENE-EXPRESSION IN CORTICAL AREAS GIVE INSIGHT INTO FUNCTIONAL ABNORMALITIES OCCURRING IN SCHIZOPHRENIA. SCHIZOPHR RES. 11:126-126.
  • HENNESSY RE; BARNES TRE; HALSTEAD SM. (Jan 1994). FOLLOW-UP-STUDY OF CHRONIC AKATHISIA IN A SCHIZOPHRENIC INPATIENT POPULATION. SCHIZOPHR RES. 11:194-194.
  • BARNES TRE; PANTELIS S; COLLINSON S; NELSON HE; CARRUTHERS K; HALSTEAD SM. (Jan 1994). RELATIONSHIP BETWEEN TARDIVE-DYSKINESIA, INTELLECTUAL IMPAIRMENT AND BRADYPHRENIA IN A CHRONIC-SCHIZOPHRENIC INPATIENT POPULATION. SCHIZOPHR RES. 11:193-193.
  • ADAMS CE; BARNES TRE; ESSALI MA; HIRSCH SR; MACKAY AVP; CORRIGAN FM; CUTTING JC; EKDAWI MY; et alMCKENNA PJ; MILLN PTS; PARKER AL; LADER M; BROWNSEY RL. (Aug 1993). THE SAFETY AND EFFICACY OF CLOZAPINE IN SEVERE TREATMENT-RESISTANT SCHIZOPHRENIC-PATIENTS IN THE UK. BRIT J PSYCHIAT. 163:150-154.
  • PANTELIS C; BARNES TRE. (1993). ACUTE EXACERBATION OF PSYCHOSIS WITH BUSPIRONE. J PSYCHOPHARMACOL. 7:295-300.
  • LIDDLE PF; HAQUE S; MORRIS DL; BARNES TRE. (1993). DYSPRAXIA AND AGNOSIA IN SCHIZOPHRENIA. BEHAV NEUROL. 6:49-54.
  • EAPEN V; KATONA CLE; BARNES TRE; ROBERTSON MM. (1993). SULPIRIDE-INDUCED TARDIVE-DYSKINESIA IN A PERSON WITH GILLES-DE-LA-TOURETTE SYNDROME. J PSYCHOPHARMACOL. 7:290-292.
  • HIRSCH SR; BARNES TRE; DICKINSON M; FERNANDEZ M; JOLLEY A; PUSAVAT L; RICCIO M; SPELLER J; et alMCCREADIE RG; STEWART M; STANDISHBARRY H; GOPPINATH HV; METCALFE M; SONI S; DAVIDSON P; COOKSON J; SILVERSTONE T; MALLETT P; DINAN TG; CHANAS A; UPPFELDT G; MATHIE B. (Nov 1992). A DOUBLE-BLIND COMPARISON OF RACLOPRIDE AND HALOPERIDOL IN THE ACUTE PHASE OF SCHIZOPHRENIA. ACTA PSYCHIAT SCAND. 86:391-398.
  • BARNES TRE. (Sep 1992). PSYCHOSOCIAL TREATMENT OF SCHIZOPHRENIA - HERZ,MI, KEITH,SJ, DOCHERTY,JP. BRIT J PSYCHIAT. 161:436-437.
  • BARNES TRE; SPELLER JC; CURSON DA; PANTELIS C; ALBERTS JL. (Jan 1992). A ONE-YEAR DOSE REDUCTION STUDY IN CHRONIC-SCHIZOPHRENIC INPATIENTS - AMISULPRIDE VS HALOPERIDOL. SCHIZOPHR RES. 6:107-107.
  • DEBELLEROCHE J; VIRGO L; BARNES T; HIRSCH SR. (Jan 1992). ANALYSIS OF GENE-EXPRESSION IN SCHIZOPHRENIA BY INSITU HYBRIDIZATION. SCHIZOPHR RES. 6:154-155.
  • Barnes TR. (Jan 1992). Clinical assessment of the extrapyramidal side effects of antipsychotic drugs. J Psychopharmacol. 6:214-221. DOI.
  • BARNES TRE. (1991). THE NEUROLEPTIC NONRESPONSIVE PATIENT - CHARACTERIZATION AND TREATMENT - ANGRIST,B, SCHULZ,SC. J PSYCHOSOM RES. 35:743-743.
  • BARNES TRE. (Mar 1990). PROPHYLACTIC USE OF ANTICHOLINERGICS IN PATIENTS ON LONG-TERM NEUROLEPTIC TREATMENT - A CONSENSUS STATEMENT - COMMENT. BRIT J PSYCHIAT. 156:413-414.
  • CURSON DA; PATEL M; LIDDLE PF; BARNES TRE. (1 Oct 1988). PSYCHIATRIC MORBIDITY OF A LONG STAY HOSPITAL POPULATION WITH CHRONIC-SCHIZOPHRENIA AND IMPLICATIONS FOR FUTURE COMMUNITY CARE. BRIT MED J. 297:819-822.
  • MANCHANDA R; HIRSCH SR; BARNES TRE. (Sep 1988). CRITERIA FOR EVALUATING IMPROVEMENT IN SCHIZOPHRENIA IN PSYCHOPHARMACOLOGICAL RESEARCH (WITH SPECIAL REFERENCE TO GAMMA-ENDORPHIN FRAGMENTS). BRIT J PSYCHIAT. 153:354-358.
  • BARNES TRE. (2 Apr 1988). TARDIVE-DYSKINESIA. BRIT MED J. 296:1004-1004.
  • BARNES TRE; HALSTEAD SM. (Mar 1988). A SCALE FOR RATING DRUG-INDUCED AKATHISIA. SCHIZOPHR RES. 1:249-249.
  • BARNES TRE; CURSON DA; LIDDLE PF. (Mar 1988). THE NATURE AND PREVALENCE OF DEPRESSION IN CHRONIC-SCHIZOPHRENIC INPATIENTS. SCHIZOPHR RES. 1:109-109.
  • LIDDLE PF; BARNES TRE. (Mar 1988). THE SUBJECTIVE EXPERIENCE OF DEFICITS IN SCHIZOPHRENIA. COMPR PSYCHIAT. 29:157-164.
  • CURSON DA; HIRSCH SR; PLATT SD; BAMBER RW; BARNES TRE. (20 Sep 1986). DOES SHORT-TERM PLACEBO-TREATMENT OF CHRONIC-SCHIZOPHRENIA PRODUCE LONG-TERM HARM. BRIT MED J. 293:726-728.
  • CURSON DA; PLATT S; HIRSCH SR; BARNES TRE; BAMBER RW. (1986). DOES PLACEBO-TREATMENT HARM PATIENTS - A 7 YEAR FOLLOW-UP OF PLACEBO-TREATED CHRONIC-SCHIZOPHRENIC OUTPATIENTS. INT J NEUROSCI. 31:85-85.
  • BARNES TRE; KATONA CLE. (Jan 1986). SUSCEPTIBILITY TO DRUG-INDUCED HYPOTENSION IN POSTPARTUM PSYCHOSIS. INT CLIN PSYCHOPHARM. 1:74-76.
  • CURSON DA; BARNES TRE; BAMBER RW; PLATT SD; HIRSCH SR; DUFFY JC. (1985). LONG-TERM DEPOT MAINTENANCE OF CHRONIC-SCHIZOPHRENIC OUT-PATIENTS - THE 7-YEAR FOLLOW-UP OF THE MEDICAL-RESEARCH-COUNCIL FLUPHENAZINE PLACEBO TRIAL .1. COURSE OF ILLNESS, STABILITY OF DIAGNOSIS, AND THE ROLE OF A SPECIAL MAINTENANCE CLINIC. BRIT J PSYCHIAT. 146:464-480.
  • KATONA CLE; BARNES TRE. (1985). PHARMACOLOGICAL STRATEGIES IN DEPRESSION. BRIT J HOSP MED. 34:168-171.

Books

  • James D; Farnham F; Moorey H; Lloyd H; Hill K; Blizard R; Barnes TRE. Outcome of psychiatric admission through the courts. RDS Occasional Paper No. 79. Home Office, London (2002).

Chapters in books

  • Dursun S; Haddad PM; Barnes TRE. Extrapyramidal symptoms. In Adverse syndromes and psychiatric drugs. 1-20. Haddad P (ed); Dursun S (ed); Deakin B (ed). Oxford University Press, Oxford (2004).
  • Barbenel DM; Barnes TRE. Movement disorders in unmedicated schizophrenia. In Drug-Induced Movement Disorders. 15-36. Sethi KP (ed). Marcel Dekker, New York (2004).
  • Barnes TRE; Kerwin R. Mortality and sudden death in schizophrenia. In Cardiovascular Risk Associated with Schizophrenia and its Treatment. 7-23. Camm J (ed). Galliard Healthcare Communications, London (2003).
  • Barnes TRE. Risk factors for dyskinesia in the elderly. In Principles and Practice of Geriatric Psychiatry. 2nd:527-533. (2002).

Conferences

  • Leeson V; Barnes TRE; Harrison I; Ron MA; Joyce EM. DO PEOPLE DEVELOPING PSYCHOSIS IN THE CONTEXT OF CANNABIS USE HAVE BETTER COGNITIVE FUNCTION BECAUSE THEY HAVE FEWER NEURODEVELOPMENTAL RISK FACTORS?. 25:A76-A76. (Aug 2011).
  • Barnes TRE; McIntyre S; Bhatti S; Paton C. MEDICINES RECONCILIATION: ADHERENCE TO MEDICATION ON ADMISSION TO A PSYCHIATRIC WARD. 25:A65-A65. (Aug 2011).
  • Paton C; McIntyre S; Barnes TRE. SCREENING FOR THE METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC MEDICATION IN PATIENTS UNDER THE CARE OF ASSERTIVE OUTREACH TEAMS: RESULTS OF A POMH AUDIT-BASED QUALITY IMPROVEMENT PROGRAMME. 25:A65-A65. (Aug 2011).
  • Joyce EM; Leeson VC; Ron MA; Barnes TR. THE IMPACT OF COGNITIVE RESERVE ON SCHIZOPHRENIA: NEURAL UNDERPINNINGS AND CLINICAL OUTCOMES. 37:245-245. (Mar 2011).
  • Barnes TR; Paton C; Shingleton-Smith A; Pope A; McIntyre S; Haddad P; Baker J; Antoniou J. A QUALITY IMPROVEMENT PROJECT TO IMPROVE THE ASSESSMENT OF SIDE EFFECTS IN PATIENTS PRESCRIBED DEPOT ANTIPSYCHOTIC MEDICATION. 24:A15-A15. (Aug 2010).
  • Hayhurst KP; Barnes TRE; Jones P; Hayhurst KP; Dunn GD; Lewis SW. LARGE EFFECT OF BASELINE TREATMENT WITH LONG-ACTING ANTIPSYCHOTIC DRUGS ON RANDOMISED TREATMENT OUTCOMES. 24:A14-A14. (Aug 2010).
  • Chu EM; Altmann DR; Barnes TRE; Joyce EM; Ron MA. COLOUR VISION IMPAIRMENT IN SCHIZOPHRENIA IS NOT EXPLAINED BY IMPAIRED ATTENTION OR COGNITIVE DEFICITS. 117:293-293. (Apr 2010). DOI.
  • Leeson V; Joyce EM; Harrison I; Barnes TRE. DOES THE EARLY COURSE OF COGNITIVE FUNCTION IN FIRST-EPISODE SCHIZOPHRENIA PREDICT FUNCTIONAL OUTCOME?. 117:280-280. (Apr 2010). DOI.
  • Barnes T; Jones P; Dunn G; Hayhurst K; Drake R; Lewis S. LARGE EFFECT OF BASELINE TREATMENT WITH LONG ACTING ANTIPSYCHOTIC DRUGS ON RANDOMIZED TREATMENT OUTCOMES. 117:380-380. (Apr 2010). DOI.
  • Joyce EM; Leeson VC; Sharma P; Harrison M; Ron MA; Barnes TR. WORKING MEMORY NOT PROCESSING SPEED IS THE BASIS OF HIGHER-ORDER PLANNING DEFICITS IN FIRST EPISODE SCHIZOPHRENIA. 117:175-175. (Apr 2010). DOI.
  • Chu EM; Kolappan M; Barnes TRE; Joyce EM; Ron MA. Retinal Nerve Fibre Layer Imaging as a Possible Biomarker of Schizophrenia. 65:207S-207S. (15 Apr 2009).
  • de Belleroche J; Maycox P; Kelly F; Taylor A; Reid J; Viknaraja R; Jones N; Lennon M; et alDavies C; Hagan J; Scorer C; Angelinetta C; Akbar T; Mortimer A; Barnes T; Hirsch S. ANALYSIS OF GENE EXPRESSION IN TWO LARGE SCHIZOPHRENIA COHORTS IDENTIFIES MULTIPLE EXPRESSION CHANGES ASSOCIATED WITH NERVE TERMINAL FUNCTION. 35:94-95. (Mar 2009).
  • Barnes TRE; Brooke D; Petch E; Shingleton-Smith A; Paton C. PREVALENCE OF, AND RATIONALE FOR, THE PRESCRIPTION OF HIGH DOSE AND COMBINED ANTIPSYCHOTICS IN FORENSIC PSYCHIATRY INPATIENT SETTINGS IN THE UK: A COMPARISON WITH ACUTE ADULT INPATIENT SETTINGS. 35:345-345. (Mar 2009).
  • Chu EM; Jackson JS; Cercignani M; Price G; Barnes TRE; Joyce EM; Ron MA. First episode psychosis and white matter integrity: Gender differences revealed using tract based spatial statistics (TBSS). 63rd Annual Convention of the Society-of-Biological-Psychiatry. 63:53S-54S. (1 Apr 2008).
  • Barnes TRE; Whittington C; Paton C. Clozapine augmentation with another antipsychotic for treatment-resistant schizophrenia: a meta-analysis. 17:S201-S201. (Oct 2007).
  • Barnes TR; Paton C; Hancock E; Cavanagh M; Taylor D; Lelliott P; POMH-UK Project Team. Screening for the metabolic syndrome in people receiving antipsychotic medication in assertive outreach teams: Results of the POMH-UK baseline audit. 10th International Congress on Schizophrenia Research. 33:494-494. (Mar 2007).
  • Barnes TRE; Leeson VC; Mutsatsa SM; Hutton SB; Joyce EM. Duration of untreated psychosis as a predictor of initial treatment response in first episode schizophrenia. 86:S115-S115. (Oct 2006).
  • Harrison I; Joyce EM; Mutsatsa S; Barnes TRE. Symptom correlates of cannabis use in first-episode psychosis. 5th International Conference on Early Psychosis. 86:S101-S101. (Oct 2006).
  • Harrison I; Joyce EM; Mutsatsa SH; Barnes TRE. Cannabis use and symptom profile at first presentation of illness: The West London first episode psychosis study. 13th Biennial Winter Workshop on Schizophrenia Research. 81:237-237. (Jan 2006).
  • Price G; Cercignani M; Parker GJ; Bagary MS; Barnes TRE; Barker GJ; Joyce EM; Ron MA. Diffusion tensor magnetic resonance imaging tractography in first-episode schizophrenia. 13th Biennial Winter Workshop on Schizophrenia Research. 81:164-164. (Jan 2006).
  • Kapasi M; Barnes TRE; Harrison I; Mutsatsa SH; Joyce EM. Measuring current and premorbid IQ in healthy volunteers and first episode psychosis: A comparison of NART, WTAR and a short WAIS III. 13th Biennial Winter Workshop on Schizophrenia Research. 81:124-124. (Jan 2006).
  • Mutsatsa SH; Joyce EM; Hutton SB; Barnes TRE. Prospective study of adherence with medication in schizophrenia: The West London first episode study. 81:249-249. (Jan 2006).
  • Yusufi B; Mukherjee S; Aitchison K; Dunn G; Page E; Barnes TRE. Reliability of the antipsychotic non-neurological side effects rating scale (ANNSERS). 19:A10-A10. (Sep 2005).
  • Barnes TR; Hutton SB; Mutsatsa SH; Joyce EM. Duration of untreated psychosis as a predictor of one-year outcome: The West London First Episode Schizophrenia Study. 20th International Congress on Schizophernia Research. 31:195-196. (Apr 2005).
  • Huddy VC; Aron AR; Clark L; Robbins TW; Kapasi A; Mutsatsa SH; Harrison I; Barnes TR; et alJoyce EM. Motor and executive inhibitory function in a schizophrenia: The west London first episode study. 31:359-360. (Apr 2005).
  • Joyce E; Hutton SB; Foster C; Mutsatsa SH; Harrison I; Barnes TR. Neurocognitive predictors of outcome 5 years after a first episode of schizophrenia: The West London Study. 20th International Congress on Schizophernia Research. 31:328-328. (Apr 2005).
  • Barnes TRE. Comparing side-effects across the atypical antipsychotics. 14:S131-S131. (Oct 2004).
  • Harrison I; Joyce EM; Mutsatsa SM; Hutton SB; Huddy V; Kapasi M; Barnes TRE. Naturalistic follow-up study of comorbid substance use in schizophrenia: The West London first episode study. 18:A56-A56. (Sep 2004).
  • Kapasi M; Hutton S; Mutsatsa S; Barnes T; Joyce E. Treatment effects of conventional and typical antipsychotics on cognition following a first episode of schizophrenia. 18:A63-A63. (Sep 2004).
  • Kapasi M; Hutton S; Mutsatsa S; Barnes T; Joyce E. Treatment effects of conventional and typical antipsychotics on cognition following a first episode of schizophrenia. 18:A67-A67. (Sep 2004).
  • Lewis SW; Davies L; Jones PB; Barnes TRE; Murray RM; Kerwin R; Taylor D; Hayhurst KP; et alLloyd H; Markwick A. A randomised, controlled trial of new atypical drugs versus clozapine in treatment-resistant schizophrenia. 67:6-7. (15 Feb 2004).
  • Lloyd HM; Markwick A; Page E; Lewis SW; Barnes TRE. Attitudes to atypical and conventional antipsychotic treatment in clinicians participating in the CUTLASS study. 67:147-147. (15 Feb 2004).
  • Mutsatsa SH; Joyce EM; Hutton SB; Barnes TRE. Correlates of duration of initial hospitalisation and time to readmission in schizophrenia: The west London first episode study. 12th Biennial Winter Workshop on Schizophrenia. 67:199-199. (15 Feb 2004).
  • Harrison I; Joyce EM; Mutsatsa SM; Hutton SB; Huddy V; Barnes TRE. Follow-up of comorbid substance use in schizophrenia: The west London first episode study. 67:216-217. (15 Feb 2004).
  • Huddy V; Hodgson TL; Mutsatsa SH; Harrison I; Barnes TRE; Joyce EM. Saccadic set-shifting and reward-dependent inhibition of return in first-episode psychosis. 12th Biennial Winter Workshop on Schizophrenia. 67:135-135. (15 Feb 2004).
  • Kapasi M; Hutton SB; Mutsatsa SH; Barnes TRE; Joyce EM. The effect of treatment with atypical and conventional antipsychotics on cognition following a first episode of schizophrenia: The west London study. 67:206-206. (15 Feb 2004).
  • Barnes TRE; Mutsatsa SH; Hutton SB; Joyce EM. Clinical correlates of comorbid substance use: West London First-Episode Schizophrenia Study. Summer Meeting of the British-Association-for-Psychopharmacology. 17:A54-A54. (Sep 2003).
  • Murthy NV; McRobbie D; Quest R; Papadaki A; Barnes TRE; Maier M. Structural brain abnormalities associated with tardive dyskinesia in people with schizophrenia: A voxel-based morphometry study. Summer Meeting of the British-Association-for-Psychopharmacology. 17:A55-A55. (Sep 2003).
  • Barnes TR; Mutsatsa SH; Hutton SB; Joyce EM. Clinical correlates. of comorbid substance use in first episode schizophrenia. 9th International Congress on Schizophrenia Research. 60:11-11. (15 Mar 2003).
  • Yusufi BZ; Mukherjee S; Flanagan RJ; Dunn G; Page E; Barnes TR. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with medication variables. 9th International Congress on Schizophrenia Research. 60:371-371. (15 Mar 2003).
  • McLeod H; Zoha M; Nauroze S; Burgess AP; Nelson HE; Barnes TR. The longitudinal stability of autobiographical memory retrieval deficits in delusional inpatients. 9th International Congress on Schizophrenia Research. 60:175-176. (15 Mar 2003).
  • KANE JM; DAUPHINAIS D; BARNES TRE; ADLER LA; RIFKIN A. ASSESSING NEGATIVE SYMPTOMS AND EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENIA - WORKSHOP REPORT. 29:45-49. (1993).
Share this on DeliciousTweet thisDigg thisStumble thisShare this on Facebook